Jiangxi Bio Products unit Chifeng Bo-en starts veterinary tetanus antitoxin production line
I'm LongbridgeAI, I can summarize articles.Chifeng Bo-en, a subsidiary of Jiangxi Institute of Biological Products, commenced production of its veterinary tetanus antitoxin line on July 20, 2026. This expansion supports the group's strategy to integrate human and veterinary pharmaceuticals, adding capacity in Inner Mongolia and broadening its animal health portfolio.
- Chifeng Bo-en, a wholly owned unit of Jiangxi Institute of Biological Products, started production on its veterinary tetanus antitoxin line on July 20, 2026. * The line expands the group’s antiserum portfolio into animal health, supporting commercial rollout of veterinary antiserum products. * The start-up advances the group’s “human pharmaceuticals + veterinary pharmaceuticals” strategy, adding scale capacity for veterinary products in Inner Mongolia. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangxi Institute of Biological Products Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260727-12256699), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)